Cargando…
Adoptive T-cell therapy for Hodgkin lymphoma
Although CAR T-cell therapy is US Food and Drug Administration–approved for B-cell non-Hodgkin lymphomas, the development of adoptive immunotherapy for the treatment of classic Hodgkin lymphoma (cHL) has not accelerated at a similar pace. Adoptive T-cell therapy with Epstein-Barr virus–specific cyto...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society of Hematology
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945637/ https://www.ncbi.nlm.nih.gov/pubmed/34610100 http://dx.doi.org/10.1182/bloodadvances.2021005304 |